anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lipstick comprising an interior part (core) and an outer part (sheath) having different compositions, wherein the core comprises at least ceramides, preferably of vegetable origin, and pyrrolidone carboxylic acid or an ester of this, and the sheath contains pigments to confer the desired colour to the lips, in association with high molecular weight hydrophobic and lipophilic polymers capable of forming an absorption network to retain the pigments on the surface of the lips, and an extract of aloe.  Preferably the core part may additionally contain at least one component selected from essential wax of rose geranium, non-saponifiable karite material, glycyrrhizinic acid and derivatives, vitamins A and E and precursors and derivatives of these, and/or at least one agent to protect the lips against the effects of atmospheric pollutants and solar radiation. The protective agent is e.g. a fluorinated oil. Preferably these components make up about 9 wt. % of the core. The polymer combination in the sheath part preferably includes at least one polymer selected from polymethylmethacrylate, methylstyrene/vinyltoluene copolymer, polyethylene and polyoxypropylated dicyclohexylmethylenediisocyanate. Preferably the polymer combination makes up about 10 wt. % of the sheath. The sheath may also contain mica and/or starch. The pigments, mica and/or starch may be coated with an aminoacid capable of improving the adhesion of the lipstick film to the cutaneous surface.
UNLABELLED: We investigated the effects of Candida albicans colonization on inflammatory responses in the murine glandular stomach, which is similar to the glandular mucosa of the human stomach. We also explored whether the presence of a food allergy could exacerbate C. albicans-induced inflammation or if C. albicans would amplify allergic inflammation in the glandular stomach. C. albicans successfully colonized the stomach of amoxicillin-pre-treated BALB/c mice and induced gastritis in the limiting ridge with minimal inflammation in the glandular stomach. There was significant upregulation of Il18, calprotectin (S100a8 and S100a9), and several antimicrobial peptides, but minimal induction of type 1, 2, or 3 responses in the glandular stomach. A robust type 2 response, inflammatory cell recruitment, and tissue remodeling occurred in the glandular stomach following oral ovalbumin challenges in sensitized mice. The type 2 response was not augmented by C. albicans colonization, but there was significant upregulation of Il1b, Il12a, Tnf, and Il17a in C. albicans-colonized food allergic mice. The presence of C. albicans did not affect the expression of genes involved in barrier integrity and signaling, many of which were upregulated during food allergy. Overall, our data indicate that C. albicans colonization induces minimal inflammation in the glandular stomach but augments antimicrobial peptide expression. Induction of a food allergy results in robust type 2 inflammation in the glandular stomach, and while C. albicans colonization does not exacerbate type 2 inflammation, it does activate a number of innate and type 3 immune responses amid the backdrop of allergic inflammation.
IMPORTANCE: Food allergy continues to be a growing public health concern, affecting at least 1 in 10 individuals in the United States alone. However, little is known about the involvement of the gastric mucosa in food allergy. Gastrointestinal Candida albicans colonization has been reported to promote gastrointestinal inflammation in a number of chronic diseases. Using a mouse model of food allergy to egg white protein, we demonstrate regionalization of the inflammatory response to C. albicans colonization, induction of robust type 2 (allergic) inflammation in the stomach, and augmentation of innate and type 3 responses by C. albicans colonization during food allergy.
Many gene mutations have been detected in lung cancer, which might differ between the primary tumor and the metastases in a same patient. One may cause by the heterogenicity of the tumor, another may cause by the sensitivity of the detection technique. So we determine to use NGS, which is a more sensitive technique, to detect the different gene mutations among the primary tumor, metastatic LN and peripheral blood in advanced nonsquamous NSCLC.

The study was designed as a prospective and single center study. Thirty five patients will be enrolled into the study and the clinical data of the patients, including his smoke history, cancer history, occupation exposure and so on, will be collected and recorded in a case report form. For the patients recruited in the study, the primary tumor and metastatic lymph nodes will be obtained by interventional pulmonology technology. And about 10ml peripheral blood will be collected at the same time. The tissue will be sent to Pathology Department of Shanghai Chest Hospital and will be processed with paraffin-embedded, and for those diagnosed with nonsquamous NSCLC, the rest tissue will be extracted with DNA and performed NGS for the qualified DNA sample using Illumina Nextseq500 sequencer.The matched peripheral blood will also be extract with DNA and performed NGS using Illumina Nextseq500 sequencer.
After being randomized into two groups, the assigned experimental group, prior to surgery and after consenting, will be asked to complete the Gastrointestinal Quality of Life Index. In addition the experimental group will be given their supply of LactoWise®. They will be required to take 1 capsule per day (300 mg of bacillus coagulans and galactomannans at 4.5 billion live cells) at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
The invention discloses a Chinese medicinal composition for treating hepatofibrosis, which is mainly prepared from the following main raw materials: 10-20g of trionyx sinensis shell, 10-20g of tortoise shell, 9-15g of curcuma zedoary, 12-15g of rhizoma sparganii, 18-25g of black sesame seeds, 15-18g of glossy privet fruit and 30g of dry loach powder. The following raw materials of the Chinese medicinal composition can be added selectively to treat the I-type symptoms of hepatofibrosis: 6-12g of fructus aurantii, 10g of coked malt, 10g of coked hawthorn, 10g of coked medicated leaven, and in addition, 12-18g of oriental wormwood and 10-15g of cape jasmine can be added to treat internal dampness and heat and jaundice. The following raw materials of the Chinese medicinal composition can be added selectively to treat the II-type symptoms of hepatofibrosis: 20-30g of dandelion, 6-9g of pseudo-ginseng, 6-9g of red peony root, 8-12g of curcuma aromatica, and in addition, 6-9g of hairyvein agrimony and 9-12g of eclipta alba can be added to treat hemorrhage. The following raw materials of the Chinese medicinal composition can be added selectively to treat the III-type symptoms of hepatofibrosis: 12-18g of codonopsis pilosula, 8-10g of dogwood and 9-12g of caulis spatholobi. 9-15g of subprostrate sophora and 1.5g of cordyceps sinensis can be added and decocted together with the raw materials to treat the positive marker of hepatitis B virus. The Chinese medicinal composition has a significant effect on 502 patients (69.05%) of the total 727 patients with the hepatofibrosis, is effective to 189 patients (26.00%), and is invalid to 36 patients (4.95%), thereby having the total effective rate of 95.05%.
After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).
PURPOSE:To obtain a percutaneous absorption promoter having excellent percutaneous absorption promotion effects on medicinal component, improved safety and feeling in use, containing an ampholytic surface active agent, a half polar surface active agent and a specific nonionic surface active agent as active ingredients. CONSTITUTION:The titled promoter containing an ampholytic surface active agent (e.g. N,N-dimethyl-Np-lauryl-N-carboxymethylammonium betaine, etc.), one or more half polar surface active agents (lauryldimethylamine oxide, etc.) and one more nonionic surface active agents containing a nitrogen atom in the molecule (e.g. fatty acid alkanolamide, etc.). Predonisolone, indomethacin, chlorpheniramine, etc., may be cited as a drug capable of increasing the medicinal effects by the use of the percutaneous absorption promoter as the active ingredient.
The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble under physiological conditions. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. <CHEM>   The compounds of formula I according to the present invention being suitable pharmaceutical agents are those wherein   Ar<1> and Ar<2> are independently from each other substituted or unsubstituted aryl or heteroaryl groups,   X is O or S, preferably O; R<1> is hydrogen or a C1-C6-alkyl group, or R<1> forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar<1>; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1; Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl which is substituted with at least one ionisable moiety to which a lipophilic chain is attached and which is containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide.ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide.
The permanent first molar teeth were cleaned using a polishing brush and pumice and isolated with cotton rolls. Caries status was assessed using DIAGNOdent pen (DIAGNOdent pen 2190, KaVo, Biberach, Germany) at the occlusal and proximal sites. Teeth having DIAGNOdent readings of 12 or less at the occlusal site and 7 or less at the proximal site were included in the study. Then, the teeth were divided into three groups. The first group (Grup A) of teeth were etched with phosphoric acid, the second group of teeth (Group L) were etched with Er:YAG laser and the third group of teeth (Group A+L) were etched with both Er:YAG laser and phosphoric acid. The patients were recalled for follow up examination at the 3rd, 6th and 9th months. The teeth were assessed using mouth mirror and explorer regarding new caries formation and retention of the fissure sealants. The obtained data were analyzed using SPSS 24.0 (SPSS 24.0 for Windows, SPSS Inc., Chicago, IL, USA).
Ropinirole hydrochloride is a non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. 

Ropinirole has moderate in vitro affinity for opioid receptors. Ropinirole and its metabolites have negligible in vitro affinity for dopamine D1, 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, alpha1-, alpha2-, and beta-adrenoreceptors.

Parkinson's Disease: The precise mechanism of action of ropinirole hydrochloride as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain. This conclusion is supported by studies that show that ropinirole improves motor function in various animal models of Parkinson's disease. In particular, ropinirole attenuates the motor deficits induced by lesioning the ascending nigrostriatal dopaminergic pathway with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in primates. The relevance of D3 receptor binding in Parkinson's disease is unknown. 

Restless Legs Syndrome (RLS): The precise mechanism of action of ropinirole hydrochloride as a treatment for Restless Legs Syndrome (also known as Ekbom Syndrome) is unknown. Although the pathophysiology of RLS is largely unknown, neuropharmacological evidence suggests primary dopaminergic system involvement. Positron emission tomographic (PET) studies suggest that a mild striatal presynaptic dopaminergic dysfunction may be involved in the pathogenesis of RLS.
The present invention relates to a composition for skin regeneration, anti-wrinkling, antioxidation and anti-inflammation. According to the present invention, kaempferol-7-O-beta-D-glucopyranoside promotes fibroblasts to synthesize collagen on the skin and thus has effects of regenerating skin and reducing wrinkles. Also, kaempferol-7-O-beta-D-glucopyranoside inhibits generation of free radicals and thus has an antioxidant effect. In addition, kaempferol-7-O-beta-D-glucopyranoside inhibits NO generation and thus has an anti-inflammatory effect. Therefore, the composition for skin regeneration, anti-wrinkling, antioxidation and anti-inflammation can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition for skin regeneration, anti-wrinkling, antioxidation and anti-inflammation includes a compound represented by chemical formula 1 as an active ingredient.
BACKGROUND: Chronic kidney disease (CKD) lacks effective treatments and renal fibrosis (RF) is one of CKD's outcomes. Dickkopf 3 (DKK3) has been identified as an agonist in CKD. However, the underlying mechanisms of DKK3 in CKD are not fully understood.
METHODS: H2O2-treated HK-2 cells and ureteric obstruction (UUO) mice were used as RF models. Biomarkers, Masson staining, PAS staining, and TUNEL were used to assess kidney function and apoptosis. Oxidative stress and mitochondria function were also evaluated. CCK-8 and flow cytometry were utilized to assess cell viability and apoptosis. Western blotting, IHC, and qRT-PCR were performed to detect molecular expression levels. Immunofluorescence was applied to determine the subcellular localization. Dual luciferase assay, MeRIP, RIP, and ChIP were used to validate the m6A level and the molecule interaction.
RESULTS: DKK3 was upregulated in UUO mouse kidney tissue and H2O2-treated HK-2 cells. Knockdown of DKK3 inhibited oxidative stress, maintained mitochondrial homeostasis, and alleviated kidney damage and RF in UUO mice. Furthermore, DKK3 silencing suppressed HK-2 cell apoptosis, oxidative stress, and mitochondria fission. Mechanistically, DKK3 upregulation was related to the high m6A level regulated by METTL3. DKK3 activated TCF4/β-catenin and enhanced MFF transcriptional expression by binding to its promoter. Overexpression of MFF reversed in the inhibitory effect of DKK3 knockdown on cell damage.
CONCLUSION: Upregulation of DKK3 caused by m6A modification activated the Wnt/β-catenin pathway to increase MFF transcriptional expression, leading to mitochondrial dysfunction and oxidative stress, thereby promoting RF progression.
Patients undergo active monitoring with examinations for clinical observation every 6 months. Every 12 months, patients undergo biopsies of visible lesions. Patients have cytology sampling performed at every visit. All participants will have samples collected for laboratory biomarker analysis.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of ENTYVIO or of other vedolizumab products.

Adults Treated with Intravenous ENTYVIO

The incidence of anti-drug antibodies to intravenous ENTYVIO using a drug-tolerant electrochemiluminescence (ECL) method for patients in UC Trials I and II and CD Trials I and III who had continuous ENTYVIO treatment administered as an intravenous infusion for 52 weeks was 6% (86 out of 1,427 total ENTYVIO-treated patients). Of the 86 patients who tested positive for anti-vedolizumab antibodies, 20 patients were persistently positive (at two or more consecutive study visits) and 56 developed neutralizing antibodies to vedolizumab.

Among the ENTYVIO-treated patients who developed persistent anti-vedolizumab antibodies, 14/20 patients had serum vedolizumab trough concentrations that were markedly reduced or undetectable and 15/20 patients did not achieve clinical remission at Week 52 in UC Trials I and II and CD Trials I and III. Because of the low occurrence of persistent anti-vedolizumab antibodies (1%; 20/1,427), the effect of these antibodies on the safety and effectiveness of ENTYVIO in these studies has not been fully characterized.

Adults Treated with Subcutaneous ENTYVIO

The incidence of anti-drug antibodies to ENTYVIO using a drug-tolerant ECL method for patients in SC UC Trial and SC CD Trial who had continuous treatment for 52 weeks was 3.4% (13 out of 381 total patients treated with subcutaneous ENTYVIO). Of the 13 patients who tested positive for anti-vedolizumab antibodies, 7 patients were persistently positive (at two or more consecutive study visits) and 7 patients developed neutralizing antibodies to vedolizumab. Two of the 7 patients with Crohn’s disease and none of the 6 patients with ulcerative colitis who had positive anti-vedolizumab antibodies achieved clinical remission at Week 52. There is insufficient data to assess the effect of anti-drug antibodies on pharmacokinetics, effectiveness, and safety of ENTYVIO in the SC UC and SC CD trials.
A controlled substance fraud prevention method preferably includes a camera, a database of faces with names, facial recognition software, a database of medicines prescribed to each face and a portable medicine safe. A patient goes to a doctor for some medical issue. The doctor will issue a prescription for a controlled substance, after photographing a face of the patient; and uploading the facial image to a computer server. The first computer server contains a database of faces and names. Facial recognition software will compare the uploaded face to other faces to determine if there are other names with the same face. A photograph of the patient's face is taken at the pharmacy and the image is uploaded to the computer server by pharmacist for facial recognition. The pharmacist also checks a database of names and medicines, before providing the prescription through a portable pill or liquid medicine safe.
The first phase of this study will include screening the participants' medical record for study eligibility. If potentially eligible, participants will partake in a secondary in-person screening assessment involving a fasting blood draw and weight, height, body fat, and waist circumference measurements. After the team receives the screening results and if participants continue to remain eligible, the second phase of the study (described below) will begin.

Following screening, participants will be enrolled into the 6-month study. Half of the enrolled participants will be scheduled for telenutrition counselling within the first three months of the study period. This group is called the "immediate treatment group". The other half will receive telenutrition counselling in the second three-month period. This group is called the "delayed treatment group". Participants will be informed which group they are assigned to and provided with details of the care that they will receive shortly after the screening phase is completed. Participants will have 50% chance of being assigned to the immediate treatment group and 50% chance of being assigned to the delayed treatment group.

Both groups will receive the same nutrition education and individualized nutrition counselling via videoconferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counselling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. Participants will be involved in developing personal nutrition goals and the dietitian will help address barriers to meeting goals and provide individualized feedback to improve and maintain their nutrition. Telenutrition appointments will maintain privacy and will not be recorded.

To help participate in telenutrition sessions and complete the required assessments, each participant will receive an iPad mini with a 6-month data plan. Once study participation is complete, the investigators will stop the data plan but participants will get to keep the iPads. There are 3 outcome assessment spaced 3 months apart (baseline, short-term, and intermediate term). Each will include the same outcome assessments involving surveys, body measurements, and a blood draw.
AIM: To explore the change in emergency department (ED) attendances for persistent pelvic pain (PPP) following laparoscopic treatment of endometriosis.
METHODS: A retrospective service evaluation was conducted on a convenience sample of 1 calendar year of elective gynaecological laparoscopies for PPP. Data were collected on ED visits for surgical complications, and for PPP in the 12 months prior to and following surgery.
RESULTS: Of the 195 women undergoing laparoscopy, 30 had attended the ED owing to their PPP in the preceding year. Endometriosis was found and treated in 51% of the cohort and no cause for pain was found in the other 96 women. Eighteen women suffered postoperative complications. In the subsequent 12 months, 31 of the cohort attended the ED for PPP. Likelihood of unscheduled hospital visits for post-operative complications and for exacerbations of pain in the year prior to and following surgery was independent of the presence of endometriosis lesions.
CONCLUSIONS: In a cohort of women living with PPP, laparoscopic surgery failed to reduce the need to attend the ED owing to their pain. Further investigation into interventions that can reduce the burden of pain on these women and the healthcare system is required.